Kumamoto University
- Academic, tech transfer
- Institute, hospital research
SAG-524 is a novel oral small-molecule HBV RNA destabilizer that potently reduces HBsAg and HBcrAg levels in preclinical models by competitively inhibiting PAPD5–HBV RNA binding. Developed to achieve a functional cure of chronic hepatitis B virus (HBV) infection—either as monotherapy or in combination with existing antivirals—SAG-524 demonstrates robust efficacy at doses as low as 6 mg/kg/day in HBV-infected human-liver chimeric mice and excellent tolerability in non-human primates up to 1,000 mg/kg/day. Supported by the Japan Agency for Medical Research and Development (AMED) and protected by broad global IP, SAG-524 is advancing toward a formal Phase 1 clinical trial aimed at HBsAg clearance. We are actively seeking co-development and out-licensing partners to accelerate preclinical and clinical development and bring this first-in-class functional cure candidate to endemic markets in Asia, Africa, and beyond.
Address
KumamotoNot required for this country
Japan
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}